Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Holding NTLA?
Track your performance easily

Intellia Therapeutics (NTLA) Financial Statements

3,023 Followers

Intellia Therapeutics Financial Overview

Intellia Therapeutics's market cap is currently ―. The company's EPS TTM is $-5.48; its P/E ratio is -2.82; Intellia Therapeutics is scheduled to report earnings on November 7, 2024, and the estimated EPS forecast is $-1.39. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 6.96M$ 28.93M$ -1.92M$ 11.99M$ 13.59M
Gross Profit$ 6.96M$ 28.93M$ -1.92M$ 11.99M$ 13.59M
EBIT$ -146.97M$ -114.00M-$ -122.08M$ -125.16M
EBITDA$ -139.09M$ -111.49M--$ -130.09M
Net Income Common Stockholders$ -147.18M$ -107.44M$ -132.16M$ -122.08M$ -123.68M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 691.07M$ 791.29M$ 912.22M$ 854.79M$ 908.07M
Total Assets$ 1.19B$ 1.26B$ 1.30B$ 1.24B$ 1.32B
Total Debt$ 106.30M$ 110.86M$ 115.35M$ 118.34M$ 122.33M
Net Debt$ -584.77M$ -680.43M$ -796.88M$ -736.45M$ -785.74M
Total Liabilities$ 220.47M$ 223.45M$ 250.81M$ 205.94M$ 218.35M
Stockholders Equity$ 971.06M$ 1.04B$ 1.05B$ 1.04B$ 1.10B
Cash Flow-
Free Cash Flow$ -59.20M$ -123.17M--$ -94.72M
Operating Cash Flow$ -58.19M$ -120.66M$ -93.05M$ -101.38M$ -90.42M
Investing Cash Flow$ -24.19M$ 5.90M$ 45.94M$ 79.50M$ -34.44M
Financing Cash Flow$ 41.25M$ 59.99M$ 106.48M$ 19.10M$ 1.05M
Currency in USD

Intellia Therapeutics Earnings and Revenue History

Intellia Therapeutics Debt to Assets

Intellia Therapeutics Cash Flow

Intellia Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis